{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:55:32Z","timestamp":1789703732478,"version":"4.0.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psychogenic pruritus (PP) is a chronic itch disorder associated with psychological conditions lacking any dermatological or systemic cause. Diagnosis relies on excluding other aetiologies and identifying psychological stressors. Treatments include dermatological and psychiatric interventions such as topical steroids, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, antihistamines, antipsychotics and psychotherapy. However, efficacy remains inconsistent, necessitating a systematic review of current and emerging pharmacological options. This study reviews pharmacological treatments for PP published in the past decade, evaluating efficacy and therapeutic potential. A systematic literature search was conducted using PubMed, Embase and Google Scholar (November 2014 to November 2024) following the PRISMA guidelines (PROSPERO: 1000201). In total, 1034 articles were screened by two independent reviewers. Inclusion criteria focused on human studies evaluating pharmacological treatments for PP. Seven studies met the inclusion criteria. Levels of evidence were assessed using the Joanna Briggs Institute critical appraisal checklist. SSRIs, particularly escitalopram, showed symptom improvement in case reports. Naltrexone (an opioid antagonist) led to complete itch resolution in a patient refractory to SSRIs. Gabapentin reduced pruritus severity. A neurokinin-1 receptor (NK-1R) antagonist (serlopitant) demonstrated significant efficacy in a phase II trial. Biologics such as dupilumab showed promise in chronic pruritus. Targeted therapies, including SSRIs, naltrexone, opioid pathway modulators, NK-1R antagonists and biologics, show promise in the clinical management of PP, but further research through randomized controlled trials is necessary to establish their efficacy and optimize treatment strategies.<\/jats:p>","DOI":"10.1093\/ced\/llag005","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:24:42Z","timestamp":1767702282000},"page":"951-957","source":"Crossref","is-referenced-by-count":3,"title":["Novel and existing therapeutic interventions in psychogenic pruritus"],"prefix":"10.1093","volume":"51","author":[{"given":"Hira","family":"Ghani","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Warren Alpert Medical School of Brown University , Providence, RI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Ghofrani","sequence":"additional","affiliation":[{"name":"Philadelphia College of Osteopathic Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-7566","authenticated-orcid":false,"given":"Nina","family":"Modanlo","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California at Los Angeles , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithisha","family":"Cheedalla","sequence":"additional","affiliation":[{"name":"Rowan-Virtua School of Osteopathic Medicine , Stratford, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6358-9068","authenticated-orcid":false,"given":"Mohammad","family":"Jafferany","sequence":"additional","affiliation":[{"name":"Central Michigan University , Mount Pleasant, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026052522582671700_llag005-B1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clindermatol.2011.11.004","article-title":"Psychosomatic factors in pruritus","volume":"31","author":"Tey","year":"2013","journal-title":"Clin Dermatol"},{"key":"2026052522582671700_llag005-B2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.genhosppsych.2008.03.006","article-title":"Idiopathic pruritus in psychiatric inpatients: an explorative study","volume":"30","author":"Kretzmer","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"2026052522582671700_llag005-B3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"2026052522582671700_llag005-B4"},{"issue":"Special Issue 6","key":"2026052522582671700_llag005-B5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.47750\/pnr.2022.13.S06.076","article-title":"Psychogenic pruritus: rapid response with a combination of selective serotonin reuptake inhibitors and benzodiazepine","volume":"13","author":"Beniwal","year":"2022","journal-title":"J Pharm Neg Results"},{"key":"2026052522582671700_llag005-B6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.det.2018.02.015","article-title":"Psychogenic pruritus and its management","volume":"36","author":"Buteau","year":"2018","journal-title":"Dermatol Clin"},{"key":"2026052522582671700_llag005-B7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.51271\/ICJEM-0014","article-title":"Psychogenic pruritis as a cause of prurigo nodularis","volume":"1","author":"Hamieh","year":"2023","journal-title":"Intercont J Emerg Med"},{"key":"2026052522582671700_llag005-B8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-3-030-54307-5_23","volume-title":"Psychodermatology in Clinical Practice","author":"Kazmi","year":"2021"},{"key":"2026052522582671700_llag005-B9","first-page":"199","article-title":"Oral naltrexone in the treatment of chronic psychogenic pruritus: a case report","volume":"30","author":"Aytulun","year":"2020","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"2026052522582671700_llag005-B10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21037\/acr-23-40","article-title":"A rare case report: chronic generalized idiopathic pruritus","volume":"7","author":"Agha","year":"2023","journal-title":"AME Case Rep"},{"issue":"2 Suppl.","key":"2026052522582671700_llag005-B11","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jaad.2007.07.017","article-title":"Pregabalin in the treatment of chronic pruritus","volume":"58","author":"Ehrchen","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2026052522582671700_llag005-B12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026052522582671700_llag005-B13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40257-020-00534-y","article-title":"Emerging therapeutic options for chronic pruritus","volume":"21","author":"Reszke","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2026052522582671700_llag005-B14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-662-44605-8_9","volume-title":"Pharmacology of Itch","author":"Storan","year":"2015"},{"key":"2026052522582671700_llag005-B15","first-page":"72","article-title":"Chronic pruritus responding to dupilumab \u2013 a case series","volume":"6","author":"Zhai","year":"2019","journal-title":"Medicines (Basel)"},{"key":"2026052522582671700_llag005-B16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026052522582671700_llag005-B17","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/exd.14669","article-title":"Role of kappa-opioid and \u00admu-opioid receptors in pruritus: peripheral and central itch circuits","volume":"31","author":"Kim","year":"2022","journal-title":"Exp Dermatol"},{"key":"2026052522582671700_llag005-B18","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.3390\/molecules26185517","article-title":"Antipruritic effect of nalbuphine, a kappa opioid receptor agonist, in mice: a pan antipruritic","volume":"26","author":"Inan","year":"2021","journal-title":"Molecules (Basel)"},{"key":"2026052522582671700_llag005-B19","author":"Kiniksa Pharmaceuticals Ltd"},{"key":"2026052522582671700_llag005-B20","doi-asserted-by":"crossref","first-page":"101826","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag005\/66295009\/llag005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/951\/66295009\/llag005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/951\/66295009\/llag005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:58:34Z","timestamp":1779764314000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/6\/951\/8416623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag005","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,8]]}}}